BRIEF PERIODS OF ISCHEMIA and reperfusion make the myocardium resistant to a subsequent prolonged ischemic insult (22) . Known as ischemic preconditioning, this phenomenon provides the most powerful endogenous cardioprotection yet identified (7) . It would be beneficial if this powerful myocardial protection could be mimicked pharmacologically without the deleterious effects of preconditioning ischemia. Several compounds, including adenosine, ACh, and nitric oxide donors, have been shown to mimic the protective effects of preconditioning (7, 33) . Reactive oxygen species (ROS), protein kinase C (PKC), and mitochondrial ATP-sensitive K ϩ (K ATP ) channels are major intracellular messengers of ischemic preconditioning (3, 14, 29) . However, the signaling pathway of this endogenous cardioprotection is not fully understood.
Flumazenil is a benzodiazepine receptor antagonist that is used clinically to reverse apnea and loss of consciousness associated with oversedation (5, 18) . It protects against cerebral ischemia (1, 17) . Recent results from our laboratory and others suggest that ROS and K ATP channels are potential cellular targets involved when flumazenil produces ischemic preconditioning in cardiomyocytes (36) . We wanted to further explore the mechanism of flumazenil-induced preconditioning, specifically the role of ROS, PKC, and K ATP channels, in intracellular signal transduction. For this purpose, we administered the thiol reductant 2-mercaptopropionyl glycine (2-MPG) as an antioxidant before and during the flumazenil infusion to attenuate ROS signals. In addition, we administered two PKC inhibitors and a K ATP channel antagonist after the flumazenil infusion to test the hypothesis that ROS activate PKC and the K ATP channel.
MATERIALS AND METHODS
Cardiomyocyte preparation. Ten-day-old embryonic chick ventricular myocytes were prepared using a method first described by Barry et al. (2) and later modified by Vanden Hoek et al. (31) . Briefly, hearts were harvested and placed in Hanks' balanced salt solution lacking magnesium and calcium (Life Technologies, Grand Island, NY). Ventricles were minced, and myocytes were dissociated by four to six rounds of trypsin degradation (0.025%; Life Technologies) at 37°C with gentle agitation. Then isolated cells were transferred to a solution with trypsin inhibitor for 8 min, filtered through a 100-m mesh filter, centrifuged for 5 min at 1,200 rpm at 4°C, and finally resuspended in a medium described previously (4, 8, 31) . Resuspended cells were placed in a petri dish in a humidified incubator (5% CO 2 -95% air at 37°C) for 45 min to promote early adherence of fibroblasts. Nonadherent cells were counted with a hemocytometer, and viability was measured using trypan blue (0.4%). Approximately 1 ϫ 10 6 cells in nutritive medium were pipetted onto coverslips (25 mm) and incubated for 3-4 days, after which synchronous contractions of the monolayer were noted. Experiments were performed on spontaneously contracting cells at 3 or 4 days after isolation.
Perfusion system. Glass coverslips containing spontaneously beating chick myocytes were placed in a stainless steel, 1-ml, flow-through chamber (Penn Century, Philadelphia, PA). The chamber was sealed with a Kynar film (McMasterCarr, Elmhurst, IL) placed between the coverslip and the metal hypoxic chamber to minimize O 2 exchange between the chamber wall and the perfusate and then mounted on a temperature-controlled platform (37°C) on an inverted microscope. A water-jacketed glass equilibration column mounted above the microscope stage was used to equilibrate the perfusate to known PO 2 . The standard perfusion media (Table 1) were equilibrated for 1 h before the experiment by bubbling with 21% O 2 -5% CO 2 -74% N 2 . A simulated ischemia solution (Table 1) composed of balanced salt solution (BSS) containing no glucose with 2-deoxyglucose (20 mM) added to inhibit glycolysis was bubbled with 20% CO 2 -80% N 2 for 1 h before the experiments. The pH of the perfusion solution was routinely verified (pH 7.4 for normoxic BSS and pH 6.8 for simulated ischemic BSS). Stainless steel or low-O 2 -solubility polymer tubing connected the equilibration column to the flow-through chamber to minimize ambient O 2 transfer into the perfusate. In previous studies, the low PO 2 in the chamber was confirmed under conditions identical to those of experiments using an optical phosphorescence quenching method (21, 24, 32) (Oxyspot, Medical Systems, Greenvale, NY).
Cell viability. An inverted microscope equipped for epifluorescent illumination included a xenon light source (75 W), a 12-bit digital cooled charge coupled device camera (Princeton Instruments), a shutter and filter wheel (Sutter), and appropriate excitation and emission filter cubes. Fluorescent cell images were obtained using a ϫ10 objective lens (Nikon Fluor). Data were acquired and analyzed with Metamorph software (Universal Imaging). Cell viability was quantified with the nuclear stain propidium iodide (PI, 5 M; Molecular Probes, Eugene, OR), an exclusion fluorescent dye that binds to chromatin, on loss of membrane integrity (29, 31) . PI is not toxic to cells over a course of 8 h, permitting its addition to the perfusate throughout the experiments. At the completion of each experiment, digitonin (300 M) was added to the perfusate for 1 h. Digitonin disrupted cell membrane integrity of all cells, allowing PI to enter. Percent loss of viability (cell death) was then expressed relative to the maximum value after 1 h of digitonin exposure (100%).
Measurement of ROS. ROS generation in cells was assessed using the probe 2Ј,7Ј-dichlorofluorescin (DCFH). The membrane-permeable diacetate form of the dye DCFH (DCFH-DA) was continuously present in the perfusate at 5 M. Within the cell, esterases cleave the acetate groups on DCFH-DA, thus trapping the reduced probe (DCFH) intracellularly (24) . ROS generation in the cells leads to the oxidation of DCFH, yielding the fluorescent product DCF (24) . The probe DCFH in cardiomyocytes is readily oxidized by H 2 O 2 or hydroxyl radical but is relatively insensitive to superoxide (O 2 Ϫ ) (8, 29, 31) . Fluorescence was measured using an excitation wavelength of 480 nm, dichroic 505-nm-long pass, and emitter band pass of 535 nm (Chroma Technology) with neutral density filters to attenuate the excitation light intensity. Fluorescence intensity was assessed in clusters of several cells identified as regions of interest. Background was identified as an area without cells or with minimal cellular fluorescence. Intensity values are reported as the percentage of initial values after background value was subtracted. Chemicals. Flumazenil was purchased from Hoffmann-La Roche (Nutley, NJ). 2-MPG, phorbol 12-myristate 13-acetate (PMA), 5-hydroxydecanoate (5-HD), chelerythrine, ebselen, and diethyldithiocarbamic acid (DDC) were purchased from Sigma Chemical (St. Louis, MO). Go-6976 was purchased from Calbiochem-Novabiochem (San Diego, CA). Flumazenil, 2-MPG, PMA, Go-6976, and 5-HD were dissolved in BSS buffer before administration.
Experimental design. As illustrated in Fig. 1, 13 groups of cardiomyocytes were studied. Control cells were subjected to 60 min of simulated ischemia followed by 3 h of reoxygenation. Preconditioned cells underwent 10 min of ischemia followed by 10 min of reoxygenation before being subjected to the ischemia-reoxygenation protocol used for the controls. In vehicle control and flumazenil-treated cells, equal volumes of BSS buffer (control) or flumazenil (10 M) were added to the perfusate for 10 min instead of preconditioning. In antioxidant-treated cells, 2-MPG (800 M) was given during the 1-h equilibration period before ischemia. In cells treated with PMA, Go-6976, chelerythrine, and 5-HD were given during the ischemia-and-reperfusion period to test the hypothesis that PKC and mitochondrial K ATP channels are downstream signals of flumazenil-induced ROS.
Several additional series of studies were used to assess the effects of preconditioning and flumazenil on ROS generation and to determine the role of superoxide dismutase (SOD) and glutathione peroxidase in flumazenil-generated ROS: controls, preconditioning, flumazenil, 2-MPG, 2-MPG ϩ flumazenil, DDC, DDC ϩ flumazenil, ebselen, and ebselen ϩ flumazenil.
The dose of 2-MPG, DDC, and ebselen was chosen on the basis of previous results (29, 36) in which these agents were found to virtually abolish the flumazenil-produced ROS signal. The 5-HD was used at 1 mM, because in previous studies (35, 36) this was the maximal dose without toxicity that did not prevent the flumazenil-induced increase in ROS signal.
Statistical analysis. Values are means Ϯ SE. Differences between groups for cell death and ROS production were compared using a two-factor ANOVA with repeated measures and Fisher's least significant difference test. Differences between groups were considered significant if P Ͻ 0.05.
RESULTS

Intracellular ROS generation. Flumazenil (10 M)
and preconditioning produced marked increases of DCFH oxidation (an index of ROS production) compared with controls [1,693 Ϯ 101 and 1,567 Ϯ 98 arbitrary units (AU), respectively, vs. 345 Ϯ 53 AU in controls (n ϭ 3 in each group), P Ͻ 0.05 vs. controls; Fig. 2 ]. The increase of ROS signaling by flumazenil was abolished by treatment with 2-MPG (345 Ϯ 53, n ϭ 3); 2-MPG alone had no effects on baseline DCFH oxidation in the absence of preconditioning ischemia or flumazenil (298 Ϯ 48, n ϭ 3).
Cytosol H 2 O 2 radicals are major components of ROS produced by flumazenil. Figure 2B shows that flumazenil-produced ROS were abolished by ebselen ( Flumazenil mimics ischemic preconditioning via ROS. In the control series, 60 min of ischemia and 3 h of reperfusion resulted in cell death of 49 Ϯ 5% (n ϭ 8). Ϫ to H 2 O 2 . Interestingly, diethyldithiocarbamic acid (DDC), a cytosol Cu,Zn-SOD inhibitor, attenuated ROS production of flumazenil. Furthermore, myxothiazol, a mitochondria electron transport inhibitor, did not affect ROS generation by flumazenil. These data indicate that ROS produced by flumazenil are mainly H 2 O 2 radicals that originate in cytosol and that cytosol SOD and glutathione peroxidase have important roles in their generation and degradation. DCF, 2Ј,7Ј-dichlorofluorescin. *P Ͻ 0.05.
Preconditioning with 10 min of ischemia and 10 min of reoxygenation before ischemic insult markedly reduced cell death (18 Ϯ 2%, n ϭ 6). Infusion of flumazenil (10 M) for 10 min followed by 10 min of a drug-free period reduced cell death to the same extent (22 Ϯ 3%, n ϭ 5) as did preconditioning. The preconditioning effect of flumazenil was abolished by the antioxidant 2-MPG administered during the equilibrium before ischemic insult (52 Ϯ 10%, n ϭ 6; Fig. 3 ).
2-MPG reduces cell death when administered during ischemia-reperfusion.
The antioxidant 2-MPG reduced cell death significantly when administered during ischemia-reperfusion [25 Ϯ 6% (n ϭ 5) vs. 52 Ϯ 10% (n ϭ 3); Fig. 4 ]. These results further confirm that 2-MPG functions as a free radical scavenger in our model.
ROS signals stimulate PKC. When administered during ischemia and reperfusion (after flumazenil infusion), specific PKC inhibition with Go-6976 (0.1 M) or chelerythrine (2 M) virtually abolished the protection of flumazenil [43 Ϯ 7% (n ϭ 6) and 54 Ϯ 7% (n ϭ 4); Fig. 5 ]. PKC activation with 0.2 M PMA mimicked the protective effect (17 Ϯ 4%, n ϭ 6; Fig. 6 ). In addition, PKC inhibitors (Go-6976 and chelerythrine), when given before ischemia, had no effects on flumazenil-generated ROS.
PKC activation opens the mitochondrial K ATP channel. The selective mitochondrial K ATP channel antagonist 5-HD, which was given during the ischemia-andreperfusion period, had no effect on cell death by itself (36) , but in the present study, it abolished the protective effect of flumazenil and PMA [46 Ϯ 5% (n ϭ 8) and 43 Ϯ 7% (n ϭ 6), respectively; Fig. 6 ].
DISCUSSION
We made several novel observations in our in vitro cardiomyocyte model of simulated ischemia-reperfusion. First, a transient increase in ROS generation after 10 min of flumazenil infusion correlates with preconditioning effects that reduce cardiocyte death during ischemia and reperfusion. Second, the ROS signals with flumazenil appear to activate PKC, in that PKC inhibition abolished protection by flumazenil. Third, PKC activation opens mitochondrial K ATP channels, as indicated by the ability of 5-HD to abolish protection. Our results suggest that an increase in ROS signals leads to the opening of mitochondrial K ATP channels via PKC activation. This intracellular signaling is one important pathway by which flumazenil mimics ischemic preconditioning.
Initial data demonstrated that a single 10-min ischemic period before a more sustained ischemia markedly reduced cardiocyte death compared with a single 60-min period of ischemic insult (18 Ϯ 2 vs. 49 Ϯ 5%). Subsequently, an infusion of flumazenil for 10 min, instead of 10 min of ischemia (preconditioning), reduced cardiocyte death to an extent similar to that resulting from preconditioning (22 Ϯ 3 and 18 Ϯ 2%, respectively). In addition to the beneficial effects of ischemic preconditioning or flumazenil in reducing cell death, return of spontaneous contraction was markedly higher in preconditioned and flumazenil-treated cells. These results agree with our previous findings (35, 36) and those of others (29) . Flumazenil mimics preconditioning to attenuate ischemia-reperfusion injury.
ROS are key intracellular messengers (27) but can potentially contribute to cell death when generated at high levels. The protection of flumazenil was abolished by pretreatment with 2-MPG, a thio reductant with antioxidant properties. This effect suggests that ROS signals are important second messengers in mediating cardioprotection. However, when 2-MPG was administered during prolonged ischemia-reperfusion, it markedly reduced cell death, likely via degrading free radicals generated during ischemia-reperfusion (15) . Interestingly, we also found that flumazenil, similar to ischemic preconditioning, resulted in a marked increase in DCFH oxidation, an index of ROS production. Others have reported that ROS are involved in triggering cardioprotection of ischemic and hypoxic preconditioning (8, 29) , ACh (35) , and opioids (34) . More importantly, we previously demonstrated that 10 min of flumazenil infusion resulted in the same pattern and magnitude of ROS signals observed during ischemic preconditioning (36) . Thus these findings suggest that ROS signals are crucial in producing the protection of flumazenil.
Flumazenil-generated ROS are mainly H 2 O 2 , because DCFH is more readily oxidized by H 2 O 2 than by O 2 Ϫ . In addition, ROS were abolished by ebselen, a were generated in mitochondria or other subcellular sites and then transported to cytosol. ROS generated by ischemic and hypoxic preconditioning originate from mitochondria (29) . It is reasonable to suspect that mitochondria are the source of flumazenil-induced ROS. However, we found that myxothiazol, a mitochondria electron transport inhibitor, did not affect ROS generation by flumazenil. Taken together, our data indicate that ROS produced by flumazenil are mainly H 2 O 2 radicals that originate in cytosol (Fig. 7) . Obviously, the exact mechanism by which flumazenil generates ROS is still not clear and needs further study.
Subsequently, we noticed that the cardioprotection of flumazenil was abolished when Go-6976 or chelerythrine, specific PKC inhibitors, was given after flumazenil infusion. This suggests that ROS with flumazenil activate PKC. ROS signals activate PKC (10, 11) , which may mediate cardioprotection of preconditioning (13, 19, 26) . Numerous studies (3, 11, 23) have suggested that PKC is a central mediator of preconditioning. In intact rats, inhibition of PKC partially or completely abolished the effects of preconditioning, depending on the strength of the preconditioning stimulus (13) . In a similar cardiomyocyte model of simulated ischemia and reperfusion, Liang (19) demonstrated that PKC activation was an important component of signal transduction of ischemic preconditioning and adenosine. Specific isoforms of PKC are more important in producing cardioprotection, and translocation of PKC (␦ and ⑀) may mediate the cardioprotective effect of preconditioning in rats and rabbits (16, 23) . In addition, we noticed that PKC inhibition did not affect flumazenil-generated ROS. This observation is consistent with recent results of Vanden Hoek et al. (30) , who showed that PKC inhibition with Go-6976 did not affect ROS produced by preconditioning. Therefore, our results and those of others strongly suggest that PKC is an important downstream signal of flumazenilproduced ROS.
ROS signals also lead to activation of mitochondrial K ATP channels (8, 29) , which are important in triggering and mediating the protection of preconditioning (14, 20) . We found that blockade of mitochondrial K ATP channels with 5-HD after flumazenil infusion abolished its protection, but our previous data showed that when 5-HD was given before and during the flumazenil infusion, free radical signals were not affected (36) . Therefore, K ATP channel activation is a downstream signal of flumazenil-induced ROS.
Whether PKC activation opens the K ATP channel or vice versa is unclear (9, 26, 28) . We noticed that the specific PKC activator PMA, administered during ischemia and reperfusion, reduced cell death to the same extent as did flumazenil. The protective effects of flumazenil and PMA were blocked by 5-HD given during ischemia and reperfusion, which suggests that flumazenil activates the mitochondrial K ATP channel via PKC. PKC enhances the ability of diazoxide to open the mitochondrial K ATP channel in rabbit cardiomyocytes (25) . Our results therefore suggest that PKC activates the mitochondrial K ATP channel in the protection of flumazenil. The mechanism by which mitochondrial K ATP channel activation produces cardioprotection has not been established (3) . In a recent review article, Gross and Fryer (14) suggested that activation of the mitochondrial K ATP channel leads to entry of potassium ion into the mitochondria and intramitochondrial depolarization. This action could decrease mitochondrial calcium overload and cause matrix swelling, which enhances mitochondrial energy synthesis and respiration (3) .
The mechanism of preconditioning is complicated and not fully established. Multiple signaling pathways, including adenosine, ACh, K ATP channels, ROS, PKC, and other kinases, are involved in the cardioprotection of preconditioning (7, 28) . Results of this study addressed only the importance of ROS-PKC-mitochondrial K ATP channel signaling pathway in flumazenilinduced preconditioning protection. The recent study by Vanden Hoek et al. (30) showed that adenosine had no effects on ROS production before ischemia, which further suggests that, in addition to ROS-PKC-K ATP channel signal transduction, other parallel signaling pathways exist by which preconditioning and flumazenil protect cardiomyocytes in ischemia-reperfusion.
In conclusion, we showed that flumazenil mimics ischemic preconditioning to reduce cell death in cultured cardiomyocytes. Transiently increased ROS signals (likely H 2 O 2 ) with flumazenil that activate mitochondrial K ATP channels via PKC appear to explain how flumazenil mimics ischemic preconditioning. Our data also suggest that clinical use of flumazenil could be beneficial for patients with ischemic heart disease.
